Janux Therapeutics, Inc. (NASDAQ:JANX) Insider Sells $140,994.86 in Stock

Janux Therapeutics, Inc. (NASDAQ:JANX) insider Andrew Hollman Meyer sold 3,334 shares of the firm’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $42.29, for a total transaction of $140,994.86. Following the transaction, the insider now owns 82,139 shares of the company’s stock, valued at approximately $3,473,658.31. The trade was a 3.90 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Andrew Hollman Meyer also recently made the following trade(s):

• On Thursday, January 2nd, Andrew Hollman Meyer sold 13,334 shares of Janux Therapeutics stock. The stock was sold at an average price of $54.88, for a total transaction of $731,769.92.

Janux Therapeutics Stock Down 3.2 %

Shares of NASDAQ:JANX opened at $39.37 on Friday. The stock’s 50 day moving average is $51.07 and its 200-day moving average is $48.28. Janux Therapeutics, Inc. has a twelve month low of $7.81 and a twelve month high of $71.71. The firm has a market capitalization of $2.07 billion, a price-to-earnings ratio of -33.65 and a beta of 3.16.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.18). The business had revenue of $0.44 million for the quarter, compared to analyst estimates of $1.50 million. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The business’s revenue for the quarter was down 82.6% compared to the same quarter last year. Equities research analysts anticipate that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Janux Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Plato Investment Management Ltd boosted its stake in Janux Therapeutics by 18.7% during the 3rd quarter. Plato Investment Management Ltd now owns 1,186 shares of the company’s stock valued at $54,000 after purchasing an additional 187 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Janux Therapeutics by 21.9% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock valued at $87,000 after purchasing an additional 339 shares in the last quarter. Rhumbline Advisers boosted its position in shares of Janux Therapeutics by 1.6% during the fourth quarter. Rhumbline Advisers now owns 38,153 shares of the company’s stock valued at $2,043,000 after buying an additional 599 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in Janux Therapeutics by 10.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,128 shares of the company’s stock worth $596,000 after buying an additional 1,095 shares in the last quarter. Finally, Virtu Financial LLC raised its position in Janux Therapeutics by 48.0% in the 3rd quarter. Virtu Financial LLC now owns 7,463 shares of the company’s stock valued at $339,000 after buying an additional 2,419 shares during the last quarter. Institutional investors and hedge funds own 75.39% of the company’s stock.

Analyst Ratings Changes

JANX has been the topic of several recent analyst reports. Leerink Partners boosted their target price on shares of Janux Therapeutics from $79.00 to $91.00 and gave the company an “outperform” rating in a report on Tuesday, December 3rd. Lifesci Capital upgraded Janux Therapeutics to a “strong-buy” rating in a research report on Friday, December 27th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $200.00 target price on shares of Janux Therapeutics in a report on Wednesday, December 11th. Leerink Partnrs upgraded Janux Therapeutics to a “strong-buy” rating in a report on Friday, November 22nd. Finally, BTIG Research raised their price objective on shares of Janux Therapeutics from $82.00 to $100.00 and gave the stock a “buy” rating in a research report on Tuesday, December 3rd. One analyst has rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $89.90.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.